November 2025
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

What Clinicians Should Know About ITP – Insights from Samwel Mikaye

Dr. S.0 MIKAYE/LinkedIn

Nov 11, 2025, 01:54

What Clinicians Should Know About ITP – Insights from Samwel Mikaye

Samwel Mikaye, CEO of SaMik Medical Center, posted on LinkedIn:

”IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

Definition

Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by:
• Isolated thrombocytopenia (platelets <100,000/µL)
• Caused by autoantibodies against platelet surface antigens → accelerated destruction in the spleen and reduced platelet production in the bone marrow.

Classification

1. Primary ITP
• Idiopathic (no identifiable cause).

2. Secondary ITP
• Associated with underlying conditions:
• HIV, HCV, EBV
• Autoimmune diseases (e.g., SLE)
• Drugs (heparin, quinine, sulfa drugs)
• Vaccination (rare)

Epidemiology

• Children: usually acute, post-viral, self-limiting.
• Adults: usually chronic, more common in women <40 years.

Clinical Features

• Often asymptomatic except for bleeding.
• Mucocutaneous bleeding:
• Petechiae, purpura, ecchymoses
• Epistaxis, bleeding gums, menorrhagia
• No splenomegaly (splenic enlargement suggests another diagnosis).

Key: Patient appears well despite very low platelet count.

Diagnosis

Diagnosis of exclusion.
• CBC: isolated thrombocytopenia; other cell lines normal.
• Peripheral smear: normal red/white cells, reduced platelets.
• Coagulation profile (PT/PTT): normal

If atypical features (anemia, leukopenia, splenomegaly), consider other causes (TTP, leukemia, DIC).

Tests to rule out secondary causes:
• HIV, HCV testing
• ANA (if autoimmune disease suspected)

Management

Children (acute ITP)
• Observation if mild bleeding and platelets >30,000/µL.
• If treatment needed (significant bleeding):
• Corticosteroids (Prednisone)
• OR IVIG (for rapid platelet rise)
• Anti-D immunoglobulin (if Rh+ and not splenectomized)

Adults (chronic ITP / symptomatic)
First-line treatment:
• Corticosteroids: Prednisone or Dexamethasone pulse
• OR IVIG (if severe bleeding or need rapid rise—e.g., surgery)

Second-line options (if refractory or steroid-dependent):
• Thrombopoietin receptor agonists (TPO-RAs):
• Romiplostim, Eltrombopag
• Rituximab (anti-CD20 antibody)
• Splenectomy (curative in ~60–70% cases)

Platelet transfusion only for life-threatening bleeding; not routinely effective since autoantibodies destroy transfused platelets.

Treatment Thresholds (Adults)
• Platelets ≥ 30,000/µL + no bleeding → observe
• Platelets < 30,000/µL or active bleeding → treat

Prognosis

• Children: 80% recover spontaneously.
• Adults: chronic in ~60–70%, but manageable.”

ITP